Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.

Campiotti, Leonardo

Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. [electronic resource] - European journal of cancer (Oxford, England : 1990) 05 2017 - 48-56 p. digital

Publication Type: Journal Article; Meta-Analysis; Review; Systematic Review

1879-0852

10.1016/j.ejca.2017.02.028 doi


Aged
Antineoplastic Agents--therapeutic use
Drug Substitution
Feasibility Studies
Female
Humans
Imatinib Mesylate--therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Remission Induction